249 related articles for article (PubMed ID: 11115376)
21. Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice.
Benjamin ER; Khanna R; Schilling A; Flanagan JJ; Pellegrino LJ; Brignol N; Lun Y; Guillen D; Ranes BE; Frascella M; Soska R; Feng J; Dungan L; Young B; Lockhart DJ; Valenzano KJ
Mol Ther; 2012 Apr; 20(4):717-26. PubMed ID: 22215019
[TBL] [Abstract][Full Text] [Related]
22. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
[TBL] [Abstract][Full Text] [Related]
23. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
[TBL] [Abstract][Full Text] [Related]
25. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.
Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Barisoni L; Jennette CJ; Bragat A; Castelli J; Sitaraman S; Lockhart DJ; Boudes PF
Orphanet J Rare Dis; 2012 Nov; 7():91. PubMed ID: 23176611
[TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on agalsidase beta in Fabry disease.
Keating GM; Simpson D
BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
[TBL] [Abstract][Full Text] [Related]
28. Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.
Desnick RJ; Dean KJ; Grabowski G; Bishop DF; Sweeley CC
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5326-30. PubMed ID: 228284
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice.
Sakuraba H; Murata-Ohsawa M; Kawashima I; Tajima Y; Kotani M; Ohshima T; Chiba Y; Takashiba M; Jigami Y; Fukushige T; Kanzaki T; Itoh K
J Hum Genet; 2006; 51(3):180-188. PubMed ID: 16372133
[TBL] [Abstract][Full Text] [Related]
30. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
31. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
Ohashi T; Iizuka S; Ida H; Eto Y
Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
Desnick RJ
Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
[TBL] [Abstract][Full Text] [Related]
33. Enzyme replacement therapy in Fabry disease.
Brady RO; Murray GJ; Moore DF; Schiffmann R
J Inherit Metab Dis; 2001; 24 Suppl 2():18-24; discussion 11-2. PubMed ID: 11758675
[TBL] [Abstract][Full Text] [Related]
34. Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.
Nguyen Dinh Cat A; Escoubet B; Agrapart V; Griol-Charhbili V; Schoeb T; Feng W; Jaimes E; Warnock DG; Jaisser F
PLoS One; 2012; 7(5):e33743. PubMed ID: 22574107
[TBL] [Abstract][Full Text] [Related]
35. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
36. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
37. Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.
Marchesan D; Cox TM; Deegan PB
J Inherit Metab Dis; 2012 Nov; 35(6):1107-17. PubMed ID: 22450713
[TBL] [Abstract][Full Text] [Related]
38. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
39. alpha-Galactosidase A deficient mice: a model of Fabry disease.
Ohshima T; Murray GJ; Swaim WD; Longenecker G; Quirk JM; Cardarelli CO; Sugimoto Y; Pastan I; Gottesman MM; Brady RO; Kulkarni AB
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2540-4. PubMed ID: 9122231
[TBL] [Abstract][Full Text] [Related]
40. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.
Tajima Y; Kawashima I; Tsukimura T; Sugawara K; Kuroda M; Suzuki T; Togawa T; Chiba Y; Jigami Y; Ohno K; Fukushige T; Kanekura T; Itoh K; Ohashi T; Sakuraba H
Am J Hum Genet; 2009 Nov; 85(5):569-80. PubMed ID: 19853240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
